{"id":504630,"date":"2020-08-28T13:20:01","date_gmt":"2020-08-28T13:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=504630"},"modified":"2020-08-28T13:20:01","modified_gmt":"2020-08-28T13:20:01","slug":"bronchitis-clinical-trial-insight-pipeline-assessment-companies-emerging-drugs-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bronchitis-clinical-trial-insight-pipeline-assessment-companies-emerging-drugs-by-delveinsight_504630.html","title":{"rendered":"Bronchitis Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bronchitis Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Bronchitis Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Bronchitis Pipeline Insight, 2020&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(Albany, US) DelveInsight has launched a new report on &ldquo;<strong>Bronchitis Pipeline Insight, 2020<\/strong><strong>.<\/strong>&rdquo;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bronchitis-pipeline-insight\">Bronchitis Pipeline Insight, 2020<\/a><\/strong>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Bronchitis&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Bronchitis&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Bronchitis&nbsp;<\/strong>treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;<strong>Bronchitis&nbsp;<\/strong>commercial assessment and clinical assessment of the&nbsp;<strong>Bronchitis&nbsp;<\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;<strong>Bronchitis&nbsp;<\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Key Companies covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Advanced Inhalation Therapies (AIT) Ltd<\/li>\n<li>AstraZeneca Plc<\/li>\n<li>DBV Technologies SA<\/li>\n<li>F. Hoffmann-La Roche Ltd<\/li>\n<li>Han Wha Pharma Co Ltd<\/li>\n<li>Hyundai Pharmaceutical Co Ltd<\/li>\n<li>Kyorin Pharmaceutical Co Ltd<\/li>\n<li>Merck &amp; Co Inc<\/li>\n<li>Mucosis BV<\/li>\n<li>Orbis Biosciences Inc<\/li>\n<li>And Many More<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Bronchitis&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Bronchitis&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Bronchitis&nbsp;<\/strong><em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;<strong>Bronchitis&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Bronchitis<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/91d69a4e1cbd12cbacf17ecb3db33dd1.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bronchitis-pipeline-insight\">Bronchitis<\/a>&nbsp;<\/strong>is an inflammation of the lining of your bronchial tubes, which carry air to and from your lungs. People who have bronchitis often cough up thickened mucus, which can be discolored. Bronchitis may be either acute or chronic.<\/p>\n<p style=\"text-align: justify;\">Often developing from a cold or other respiratory infection, acute bronchitis is very common. Chronic bronchitis, a more serious condition, is a constant irritation or inflammation of the lining of the bronchial tubes, often due to smoking.<\/p>\n<p style=\"text-align: justify;\">For either acute bronchitis or chronic bronchitis, signs and symptoms may include: Cough, Production of mucus (sputum), which can be clear, white, yellowish-gray or green in color &mdash; rarely, it may be streaked with blood, Fatigue, Shortness of breath, Slight fever and chills, Chest discomfort etc.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for&nbsp;<strong>Bronchitis<\/strong>&nbsp;treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of&nbsp;<strong>Bronchitis<\/strong>?&nbsp;<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of&nbsp;<strong>Bronchitis<\/strong>?<\/li>\n<li>How many&nbsp;<strong>Bronchitis&nbsp;<\/strong>emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of&nbsp;<strong>Bronchitis<\/strong>?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?&nbsp;<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact&nbsp;<strong>Bronchitis&nbsp;<\/strong>market?&nbsp;<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of&nbsp;<strong>Bronchitis<\/strong>?&nbsp;&nbsp;<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing&nbsp;<strong>Bronchitis<\/strong>&nbsp;therapies?&nbsp;<\/li>\n<li>What are the clinical studies going on for&nbsp;<strong>Bronchitis&nbsp;<\/strong>and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?&nbsp;<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for&nbsp;<strong>Bronchitis<\/strong>?&nbsp;<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of&nbsp;<strong>Bronchitis<\/strong>?&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of Bronchitis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. Competitive Intelligence Analysis for Bronchitis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. Bronchitis: Market Overview at a Glance<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Bronchitis Total Market Share (%) Distribution in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Bronchitis Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\"><strong>5. Bronchitis: Disease Background and Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6. Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Bronchitis Epidemiology and Patient Population<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Key Endpoints of Bronchitis Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Marketed Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Emerging Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. Bronchitis: Seven Major Market Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>14. Attribute analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. 7MM: Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Access and Reimbursement Overview of Bronchitis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Market Drivers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Market Barriers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>22. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>23. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: <\/strong><strong>https:\/\/www.delveinsight.com\/sample-request\/bronchitis-pipeline-insight<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bronchitis-clinical-trial-insight-pipeline-assessment-companies-emerging-drugs-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/bronchitis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/bronchitis-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/bronchitis-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bronchitis-clinical-trial-insight-pipeline-assessment-companies-emerging-drugs-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Bronchitis Pipeline Insight, 2020&#8221; (Albany, US) DelveInsight has launched a new report on &ldquo;Bronchitis Pipeline Insight, 2020.&rdquo; &nbsp; &#8220;Bronchitis Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Bronchitis&nbsp;market. A detailed &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bronchitis-clinical-trial-insight-pipeline-assessment-companies-emerging-drugs-by-delveinsight_504630.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-504630","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/504630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=504630"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/504630\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=504630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=504630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=504630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}